Best Supplements to Take With AC-SDKP (Goralatide)

AC-SDKP Works Differently From the Peptides Most Often Compared to It

Most peptides you encounter in recovery and optimization contexts work by sending a positive signal: grow more of this, heal faster, produce more of that. AC-SDKP does something fundamentally different. It works by blocking a destructive process rather than amplifying a productive one, and that distinction matters because it shifts what the compound actually needs from the body around it to do its job.

The compound's primary job is to suppress the chain of signals the body uses to trigger fibrosis, the process that turns damaged tissue into scar tissue rather than functional tissue. In the context of organ health, cardiac recovery, and chronic inflammation, this process tells fibroblasts, the cells responsible for laying down structural tissue, to transform into a more aggressive cell type that deposits collagen indiscriminately. AC-SDKP blocks a key step in that cascade by preventing the activation of a relay protein called Smad2 (which carries the fibrosis signal into the cell nucleus), stopping that transformation before it takes hold. What makes this unusual among peptides is that after more than three decades of research, no definitive cell-surface receptor for AC-SDKP has been identified. It operates through intracellular signaling rather than by docking with a receptor the way most peptides do.

At the same time, AC-SDKP suppresses a separate inflammatory switch in immune cells that drives production of pro-inflammatory alarm signals, including interleukin-6 and TNF-alpha (molecules released by immune cells that sustain the inflammatory environment fibrosis depends on). These two actions together, blocking the fibrotic cascade and reducing the inflammatory signals that sustain it, are what make AC-SDKP genuinely distinct from the peptides it is frequently grouped with. Unlike BPC-157, which works primarily through growth and regenerative signaling to promote cell proliferation and repair, AC-SDKP works by suppressing the fibrotic cascade. It is not a regenerative amplifier. It is an endogenous counter-regulator, a peptide the body produces naturally to hold its own scarring response in check.

It is frequently compared to Thymosin Beta-4, the larger protein it is derived from in the body. TB-500 and Thymosin Beta-4 work primarily to stimulate cell growth and the formation of new blood vessels. AC-SDKP does the opposite at the level of blood-forming cells: it holds certain progenitor cells in a resting, non-dividing state rather than pushing them to proliferate. They come from the same parent protein and they are not the same compound. Running both together stacks opposing effects at the stem cell level and creates uncontrolled exposure, since Thymosin Beta-4 is converted into AC-SDKP by the body's own enzymes.

It is also sometimes confused with ACE inhibitors, the blood pressure medications such as lisinopril or enalapril. The confusion has a real biological basis: ACE inhibitors block the enzyme that breaks AC-SDKP down in the bloodstream, so they raise endogenous AC-SDKP levels substantially as a secondary effect. The anti-fibrotic benefits researchers have observed from ACE inhibitors are partly explained by that rise in natural AC-SDKP. But AC-SDKP itself does not alter blood pressure, does not block ACE activity, and does not carry the cardiovascular effects of those medications. The mechanisms are related but distinct, and combining exogenous AC-SDKP with an ACE inhibitor creates a serious, pharmacokinetically uncharacterized interaction that requires clinician oversight.

Because AC-SDKP's mechanism is specifically about clearing two biological obstacles, fibrosis signaling and inflammatory signaling, the supplements that earn a place alongside it are the ones that support the same tissue environment through different routes. The cofactors that healthy connective tissue remodeling depends on. The nutrients that reduce the fibrotic and inflammatory burden AC-SDKP is working against, through pathways it does not address itself. Running this peptide against a nutritionally thin baseline is running it at a disadvantage.

The Supplements That Earn a Slot With AC-SDKP

There are no dose numbers on this page. The right amount of each of these depends on what you are running, what your bloodwork shows, and what else you are taking. That calculation belongs in a protocol, not a general guide. The MyPeptidePal app builds the personalized picture from your actual situation.

Nutritional Cofactors AC-SDKP Depends On to Finish the Job

AC-SDKP suppresses the fibrotic signal. It does not build replacement tissue. That job falls to the cellular machinery that has been doing it since long before any peptide was involved, and that machinery has specific nutritional requirements. When those requirements are not met, the peptide can successfully block the scar-tissue cascade, but the functional tissue that should replace it is limited in what it can build.

Vitamin C

Collagen is the structural backbone of nearly every tissue the body repairs. But freshly synthesized collagen is not stable in its raw form. Before it can form the strong, interlocked fibers that give tissue its mechanical integrity, it has to be chemically modified at specific points along each chain. The enzyme that performs this modification cannot run without vitamin C. Without adequate vitamin C, that stabilizing step is rate-limited, regardless of how much upstream signaling is present.

In the context of AC-SDKP, this matters because the peptide is redirecting tissue fate away from fibrotic scarring. If it succeeds in suppressing that pathway, the tissue has to resolve through functional remodeling instead. Vitamin C is the direct requirement that makes that remodeling possible at the collagen-assembly step. Its role here is backed by well-established evidence across wound healing, connective tissue diseases, and surgical recovery. It is not anecdotal in this function.

Spreading intake across the day improves how well it is absorbed compared to a single large dose, because the intestinal transport system for vitamin C becomes saturated at high concentrations and cannot handle a large amount at once.

Zinc

Zinc is a structural component of the enzymes the body uses to carefully dismantle existing tissue matrix to make room for new, better-organized tissue. These enzymes, which act like molecular scissors that cut through the old structural framework in a controlled way, require zinc to maintain their active three-dimensional shape. Without adequate zinc, this coordinated dismantling and rebuilding process runs inefficiently, and the quality of tissue remodeling suffers.

There is a layer specific to AC-SDKP worth noting. ACE, the enzyme responsible for breaking AC-SDKP down in the bloodstream, is itself a zinc-dependent enzyme. This does not produce a direct supplement interaction at typical doses, but it does mean zinc participates in both the tissue remodeling machinery AC-SDKP supports and in the clearance enzyme that determines AC-SDKP's effective exposure time. Very high zinc supplementation could theoretically modulate ACE activity, but this is not established as a meaningful concern at normal dietary or supplemental amounts. What is more practically relevant is ensuring zinc status is adequate, because a deficiency impairs the remodeling enzymes that functional tissue recovery depends on, regardless of what the peptide is doing.

The evidence for zinc's role in wound healing and collagen synthesis in humans is solid. Its direct pairing with AC-SDKP has not been studied clinically; the case rests on the well-understood enzyme biology.

Synergists That Reach the Same Targets From Different Directions

AC-SDKP operates at specific nodes in the fibrotic and inflammatory signaling networks. But these networks have multiple entry points, and compounds that approach the same endpoints through independent routes can produce genuinely additive benefit rather than simple redundancy. The two supplements in this section are on the list because their mechanisms do not overlap with AC-SDKP's. They approach the same destination from different roads.

Omega-3 Fatty Acids

Omega-3 fatty acids, specifically EPA and DHA, are among the most clinically studied anti-inflammatory supplements. Their mechanism is entirely distinct from AC-SDKP's. Rather than blocking specific signaling proteins inside the cell, EPA and DHA are incorporated into cell membranes. When those membranes are broken down, the incorporated omega-3s are converted into specialized molecules that actively drive the resolution of inflammation. These molecules work by binding to receptors on immune cells and signaling them to stand down, clear debris, and stop producing inflammatory compounds. That is a meaningfully different action from blocking a signaling protein inside the cell.

This matters because chronic unresolved inflammation is one of the conditions that sustains the fibrosis-driving signal AC-SDKP is targeting. Omega-3s, by reducing the inflammatory burden through this lipid-signaling route, can reduce the fibrotic pressure that AC-SDKP is working against. Studies in cardiac and liver fibrosis models show that EPA and DHA suppress the signal that tells cells to produce scar tissue and reduce collagen deposition, which is the same endpoint AC-SDKP pursues through its intracellular pathway. The anti-fibrotic overlap is real, not merely theoretical.

No clinical trial has tested omega-3 supplementation specifically alongside AC-SDKP. The case for the combination rests on well-documented complementary mechanisms and the solid human trial evidence for EPA and DHA's anti-inflammatory effects across multiple populations and conditions. That is a stronger evidentiary foundation than most supplement pairings in this space carry.

This is the higher-value pick in the synergist section. It is doing two jobs: reducing the inflammatory background that sustains fibrosis, and independently suppressing the fibrosis-driving signal through the lipid-signaling route that AC-SDKP's intracellular pathway does not reach.

Curcumin

Curcumin, the active compound in turmeric, suppresses both the cell's master inflammatory switch and the signal that tells cells to produce scar tissue, through entry points that differ from AC-SDKP's. It suppresses the inflammatory switch by blocking the breakdown of a protein that normally keeps it turned off. Think of that protein as a lock on the inflammatory switch: it can only activate when that lock is removed, and curcumin prevents the lock from being removed. That is a different step in the same chain AC-SDKP addresses through its action in immune cells.

Curcumin also reduces fibrosis-driving gene expression through multiple signaling routes that are distinct from AC-SDKP's own action at the relay-protein level. In studies of lung, heart, kidney, and liver fibrosis, curcumin has demonstrated anti-fibrotic activity across multiple experimental settings. Two inhibitors working at different points in the same pathway produce more complete suppression than either achieves alone.

The evidence is largely from laboratory and animal studies. Human trial data on curcumin's anti-fibrotic effects is limited, partly because standard curcumin powder has poor absorption and does not reach meaningful blood levels without formulation help. Preparations that improve absorption, such as those using phospholipid complexes or combining curcumin with piperine, a compound in black pepper that slows its breakdown, produce substantially higher circulating levels than plain powder and are what the relevant studies use. The combination with AC-SDKP specifically has not been studied in humans, and the case is mechanistic and preclinical rather than clinical.

Cautions and Interactions

ACE Inhibitors Are a Serious Interaction

If you are taking an ACE inhibitor such as lisinopril, enalapril, ramipril, captopril, or any drug in that class, discuss this with a licensed clinician before adding AC-SDKP to your protocol. This is a specific, mechanistically documented pharmacokinetic interaction, not a general caution.

ACE inhibitors work by blocking the enzyme that degrades AC-SDKP in the bloodstream. Under normal conditions, injected AC-SDKP is cleared from plasma very rapidly, within minutes. When ACE is inhibited, that clearance pathway is blocked, and plasma AC-SDKP from endogenous production alone rises substantially above the normal baseline. Adding exogenous Goralatide on top of that creates additive exposure that has not been characterized at a pharmacokinetic level in the literature. The consequence is unpredictable dose-dependent effects and a meaningfully amplified potential for suppression of blood-forming cells. This is the one interaction in AC-SDKP's profile that rises to a genuine safety concern.

Thymosin Beta-4 and TB-500

Running AC-SDKP alongside TB-500 or Thymosin Beta-4 creates pharmacokinetic overlap without clean dose control. TB-500 is the precursor protein that the body converts into AC-SDKP via specific enzymes. Co-administering both is effectively adding an uncontrolled and unpredictable additional source of AC-SDKP exposure on top of injected Goralatide. Beyond the exposure issue, their effects on blood-forming stem cells point in opposite directions: Thymosin Beta-4 promotes stem cell proliferation while AC-SDKP arrests it. No clinical interaction data exists, but the mechanistic conflict is documented and the pharmacokinetic overlap is certain.

History of Malignancy or Bone Marrow Suppression

AC-SDKP's mechanism includes holding certain stem cells in a resting, non-dividing state. In chemotherapy settings, this protective action is well established and beneficial. In individuals with a history of malignancy or existing bone marrow suppression, this same mechanism warrants caution and clinician oversight rather than self-directed use.

Pregnancy and Lactation

AC-SDKP is strictly contraindicated during pregnancy and lactation. No human safety data exists for either context, and the peptide's documented effects on stem cell cycling and tissue development create theoretical risks that cannot be excluded.

Frequently Asked Questions

How much of each supplement should I take with AC-SDKP?

There are no dose numbers in this guide, and that is deliberate. The right amount of vitamin C, zinc, omega-3s, or curcumin depends on your current bloodwork, your overall protocol, and any medications you are taking. A number printed here for the average reader would be wrong for most specific ones. MyPeptidePal takes your individual picture and builds the amounts from your actual situation.

Which blood markers matter when running AC-SDKP?

The most relevant markers to track are a complete blood count, including white blood cell and platelet counts, because AC-SDKP acts on blood-forming progenitor cells at the level of cell-cycle entry and a baseline establishes whether anything meaningful shifts. High-sensitivity CRP is useful for tracking whether the anti-inflammatory and anti-fibrotic work is moving in the right direction, and it serves as a shared readout for both AC-SDKP and its synergist supplements. If you are using omega-3 fatty acids, the omega-3 index tells you whether your intake is actually reaching therapeutic tissue levels rather than just clearing a nominal daily amount.

Does AC-SDKP behave like the healing peptides BPC-157 and TB-500?

Not exactly, and the differences matter for how you support it. BPC-157 and TB-500 work primarily through growth and regenerative signaling, promoting cell proliferation, the formation of new blood vessels, and tissue growth. AC-SDKP works in the opposite direction at the level of blood-forming cells, holding stem cells in a resting state rather than pushing them to divide. Its primary job is suppressing fibrosis and inflammation rather than stimulating repair. That means the supplement logic shifts: less about providing raw materials for rapid growth, more about supporting the tissue environment that lets anti-fibrotic remodeling proceed without the fibrotic and inflammatory signals fighting back.

Can I just eat well and skip the supplements?

For vitamin C and zinc, diet is genuinely the most relevant variable, and many people running protocols are eating well enough that their cofactor needs are covered. Bloodwork tells you more than assumptions in either direction: if your markers are in range, supplementing may add little. The argument for supplementation is strongest for omega-3 fatty acids, where the evidence for meaningful anti-inflammatory benefit requires a specific daily amount of EPA and DHA that most diets do not consistently reach, regardless of overall diet quality.

Does AC-SDKP interact with common supplements?

At typical supplemental doses, none of the supplements on this list has a documented direct interaction with AC-SDKP's mechanism. Very high zinc intake theoretically modulates the ACE enzyme that clears AC-SDKP from circulation, but this is not established as a clinically meaningful concern at normal amounts. Curcumin and omega-3s share anti-inflammatory and anti-fibrotic targets with AC-SDKP, which is why they are here, and that overlap is the goal rather than a risk. The serious interaction to be aware of is with ACE inhibitors at the medication level, covered in the cautions section above.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of AC-SDKP (Goralatide) and the nutrients that support it in one place.